CYCN (Cyclerion Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CYCN Cyclerion Therapeutics Inc CYCN
34 GF Score
Price $3.50
! 4 Warning Signs
View Full Analysis

What is Cyclerion Therapeutics OCF Margin %?

Cyclerion Therapeutics CYCN -4.16% 34 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CYCN with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 950 Biotechnology companies, Cyclerion Therapeutics ranks worse than 60.32% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Cyclerion Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-1.18 Mil. Cyclerion Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Cyclerion Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Cyclerion Therapeutics's current OCF Yield % is -23.24%.

The historical rank and industry rank for Cyclerion Therapeutics's OCF Margin % or its related term are showing as below:

CYCN' s OCF Margin % Range Over the Past 10 Years
Min: -13673.74   Med: -1683.92   Max: -159.79
Current: -176.72

During the past 9 years, the highest OCF Margin % of Cyclerion Therapeutics was -159.79%. The lowest was -13673.74%. And the median was -1683.92%.

CYCN's OCF Margin % is ranked worse than
60.32% of 950 companies
in the Biotechnology industry
Industry Median: -65.71 vs CYCN: -176.72

Cyclerion Therapeutics OCF Margin % Related Terms

Cyclerion Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Cyclerion Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclerion Therapeutics OCF Margin % Chart

Cyclerion Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only -1,099.91 -13,673.74 0.00 -216.65 -159.79

Cyclerion Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,195.06 -540.86 -30.17 -154.05 0.00

CYCN vs OSRH, LSTA, ICU: OCF Margin % Comparison

For the Biotechnology subindustry, Cyclerion Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclerion Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclerion Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Cyclerion Therapeutics's OCF Margin % falls into.


CYCN
34GF Score
Cyclerion Therapeutics Inc CYCN
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclerion Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Cyclerion Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.314/2.074
=-159.79 %

Cyclerion Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.176/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Cyclerion Therapeutics (CYCN) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cyclerion Therapeutics and its competitors. According to the industry distribution chart, Cyclerion Therapeutics ranks #573 out of 950 companies in the Biotechnology industry, placing it in the top 60.3%.
Is Cyclerion Therapeutics' OCF Margin % too high?
Cyclerion Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Cyclerion Therapeutics ranks #573 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cyclerion Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cyclerion Therapeutics' OCF Margin % compare to OSRH and LSTA?
According to the Biotechnology industry distribution chart, Cyclerion Therapeutics ranks #573 out of 950 companies for OCF Margin %. This places Cyclerion Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cyclerion Therapeutics and its competitors. Cyclerion Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclerion Therapeutics stock overvalued right now?
Cyclerion Therapeutics (CYCN) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Cyclerion Therapeutics' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Cyclerion Therapeutics (CYCN), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyclerion Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
34GF Score

Get the complete analysis for CYCN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.50
Price